Form 4: Alkermes EVP R&D Vests Performance Stock Units

Alkermes plc's EVP R&D and Chief Medical Officer, Craig C. Hopkinson, acquired 25,352 ordinary shares through the vesting of performance-based restricted stock units.

Summary

• Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc, acquired 25,352 ordinary shares on February 5, 2026.
• These shares were acquired as a result of the vesting of performance-vesting restricted stock unit awards (2023 PRSUs) granted on February 23, 2023.
• The 2023 PRSUs had a three-year performance period that concluded on December 31, 2025.
• Vesting was triggered by the achievement of pre-specified performance goals and the application of a relative total shareholder return modifier.
• This transaction represents the final vesting event under the 2023 PRSUs.
• Concurrently, 7,454 ordinary shares were disposed of at a price of $33.55 per share, likely for tax withholding purposes related to the vesting.
• Following these transactions, Craig C. Hopkinson beneficially owns 75,638 ordinary shares directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, as the vesting of performance-based awards indicates the company met its pre-defined performance targets, which is generally favorable for the company and its shareholders. However, it is a routine compensation event rather than a new strategic development.

Positives

• The vesting of performance-vesting restricted stock units indicates that Alkermes plc achieved certain pre-specified performance goals and a relative total shareholder return modifier during the performance period ending December 31, 2025.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that executive compensation structures, including performance-vesting restricted stock units, are a standard practice in the pharmaceutical and biotechnology industries. These awards are designed to align executive incentives with shareholder value creation and company performance over multi-year periods.

Comparison to Industry Standards

• The use of performance-vesting restricted stock units (PRSUs) is a common and widely accepted executive compensation mechanism across the biotech and pharmaceutical sectors, similar to practices at companies like Biogen, Gilead Sciences, and Amgen.
• The structure, tying vesting to pre-specified performance goals and a relative total shareholder return modifier, aligns with best practices for incentivizing long-term executive performance and shareholder alignment.

Stakeholder Impact

• Shareholders: The vesting of performance-based awards suggests that the company met its performance objectives, which could be viewed positively as executive compensation is aligned with company success.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction related to executive compensation, specifically the vesting of performance-based restricted stock units and subsequent tax-related share disposition. It does not provide new fundamental information or strategic insights that would warrant a change in investment recommendation for Alkermes plc.

Keywords

Alkermes, ALKS, Form 4, Insider Transaction, Stock Vesting, Restricted Stock Units, Executive Compensation, Performance Awards, Biotechnology, Pharmaceuticals